LAUSANNE, Switzerland– ADC Therapeutics SA (NYSE: ADCT) announced today it has appointed industry veteran David Gilman to the new role of Chief Business & Strategy Officer reporting to Chief Executive Officer Ameet Mallik effective July 1st. In this role, Mr. Gilman will be responsible for all business development and portfolio strategy efforts globally and he will serve on the Company’s executive leadership team.
“David Gilman is a seasoned business development and strategy executive who has an excellent track record within the life sciences industry,” said Ameet Mallik, President and Chief Executive Officer of ADC Therapeutics. “We are excited to have David join our leadership team at this pivotal moment in the evolution of ADC Therapeutics.”
Mr. Gilman is a pharmaceutical business executive with over 25 years of experience. At Novartis, he was Global Head of Portfolio Strategy and Business Development for Novartis Oncology, from 2018-2019. He joins ADC Therapeutics from ClearView Healthcare Partners, a global strategy and consulting firm focused on life sciences, where he played a key role in direct client service as well as global expansion efforts helping his clients accomplish significant business development and strategic transactions from 2019-2022. Prior to ClearView and Novartis, Mr. Gilman spent 17 years at The Frankel Group/Huron Consulting Group where he focused on facilitating numerous and significant pharmaceutical partnerships for his clients.
Mr. Gilman holds an MBA from the University of Texas, Austin and an AB from the University of Chicago.
